Comparing Treatments for Bladder Cancer Recurrence
Author Information
Author(s): Matloubieh Jubin E., Hanelin David, Agalliu Ilir, Treglia Giorgio, Vogl Ursula Maria
Primary Institution: Albert Einstein College of Medicine
Hypothesis
This study aims to evaluate the efficacy of mitomycin C, gemcitabine, and docetaxel in treating non-muscle invasive bladder cancer.
Conclusion
Both gemcitabine and mitomycin C are effective treatments that reduce tumor recurrence and improve survival for non-muscle invasive bladder cancer patients.
Supporting Evidence
- Gemcitabine showed a 24% reduction in the risk of tumor recurrence.
- Mitomycin C showed a 37% reduction in the risk of tumor recurrence.
- Recurrence-free survival for gemcitabine was 69.5%.
- Recurrence-free survival for mitomycin C was 67.2%.
- Studies showed large variability in results, indicating the need for broader patient representation.
Takeaway
This study looked at different medicines to help people with bladder cancer not come back. It found that two of the medicines worked well to keep the cancer from coming back.
Methodology
A systematic review and meta-analysis of observational cohort studies and randomized clinical trials published between 2009 and 2022.
Potential Biases
Women and minorities were generally underrepresented in the studies, raising concerns about the generalizability of the results.
Limitations
The studies included had large variability in design, treatment protocols, and patient demographics, which may affect the generalizability of the findings.
Participant Demographics
The average age of participants was approximately 67 years, with about 80% being male.
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI 0.64–0.87
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website